US2016152953A1PendingUtilityA1

Endogenous expression of hla-g and/or hla-e by mesenchymal cells

57
Assignee: ESCAPE THERAPEUTICS INCPriority: Mar 30, 2007Filed: Aug 6, 2015Published: Jun 2, 2016
Est. expiryMar 30, 2027(~0.7 yrs left)· nominal 20-yr term from priority
Inventors:Basil M. Hantash
A61K 45/06C12N 5/0663C12N 15/85A61K 35/28C12N 5/0667G01N 33/56977
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions are provided for the identification and isolation of mammalian HLA-G + MSC, HLA-E + MSC, or HLA-G + /HLA-E + MSC. The methods of the invention provide a means to obtain enriched HLA-G + MSC, HLA-E + MSC, or HLA-G + /HLA-E + MSC populations.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A substantially homogeneous cellular composition of mammalian mesenchymal stem cells (MSC) comprising an enriched population of HLA-G+ MSC, HLA-E+ MSC, and/or HLA-G+/HLA-E+ MSC. 
     
     
         2 . The composition of  claim 1 , wherein at least about 25% of the cells present in said composition are HLA-G+ MSC. 
     
     
         3 . The composition according to  claim 2 , wherein said cells that have an HLA-G+ MSC phenotype are present after initial isolation from tissue. 
     
     
         4 . The composition of  claim 1 , wherein at least about 25% of the cells present in said composition are HLA-E+ MSC. 
     
     
         5 . The composition of  claim 1 , wherein at least about 25% of the cells present in said composition are HLA-G+/HLA-E+ MSC. 
     
     
         6 . The composition according to  claim 1 , wherein said MSC are isolated from adipose tissue. 
     
     
         7 . The composition according to  claim 1 , wherein said MSC are isolated from bone marrow. 
     
     
         8 . The composition according to  claim 1 , wherein at least one MSC of said population further expresses indoleamine-pyrrole 2,3, dioxygenase (INDO). 
     
     
         9 . The composition according any one of  claims 1  and  8 , wherein at least one MSC of said population further expresses CD200. 
     
     
         10 . The composition according to  claim 1 , wherein at least one MSC of said composition comprises an exogenous nucleic acid. 
     
     
         11 . The composition according to  claim 10 , wherein said exogenous nucleic acid comprises a coding sequence for a polypeptide sequence of interest, operably connected to a promoter sequence active in said HLA-G+ MSC. 
     
     
         12 . The composition according to  claim 11 , wherein said exogenous nucleic acid comprises a sequence encoding HLA-G. 
     
     
         13 . A method for isolating mesenchymal stem cells (MSC), the method comprising:
 contacting a population of MSC with an antibody specific for HLA-G and/or HLA-E for a period of time sufficient to bind said HLA-G and/or HLA-E;   selecting for cells expressing said HLA-G and/or HLA-E.   
     
     
         14 . The method according to  claim 13 , wherein said population of cells are isolated from adipose tissue. 
     
     
         15 . The method according to  claim 13 , wherein said population of cells are isolated from bone marrow.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.